HiberCell is developing therapies that blunt the omnipresent stress-mediated adaptive response of cancer cells.

HC-5404-FU is the first therapeutic candidate from the HiberCell’s stress modulator platform that has direct anti-tumor activity while simultaneously reprogramming the immunosuppressive tumor microenvironment that is foundational to cancer cell survival.